TARPLIN STRATEGIES LLC for GENENTECH, INC.

Health Issues HCR

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit. Meetings with Administration and congressional staff on coverage/payment issues related to cancer biotherapeutics, 340B program. Meetings with Administration staff concerning the President's precision medicine initiative.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics H.R.1470 and S. 810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs. Public Law 114-10, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for Part B drugs.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; Centers For Disease Control & Prevention (CDC); Office of Management & Budget (OMB)

Bills named: H.R. 1470 (114th), S. 810 (114th)

Pharmacy PHA

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis. Held discussions with Administration staff about 340B program requirements on participating pharmaceutical manufacturers. Held preliminary discussions with Administration staff on anti-viral drugs in the strategic national stockpile.

Contacted: Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Office of Management & Budget (OMB); Executive Office of the President (EOP)